Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Page 1
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Galiè N, et al. Among authors: rubin lj. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. Adv Ther. 2022. PMID: 34727317 Free PMC article. Clinical Trial.
The ongoing open-label extension study (GRIPHON OL) collects further data on long-term safety, tolerability, and survival of PAH patients treated with selexipag. ...A large proportion of the population was receiving background therapy at selexipag initiation, providing fur …
The ongoing open-label extension study (GRIPHON OL) collects further data on long-term safety, tolerability, and survival of PAH pati …
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galiè N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, Lang I. Gaine S, et al. Among authors: rubin lj. Chest. 2021 Jul;160(1):277-286. doi: 10.1016/j.chest.2021.01.066. Epub 2021 Feb 3. Chest. 2021. PMID: 33545163 Free article. Clinical Trial.
BACKGROUND: Early initiation of pulmonary arterial hypertension (PAH) therapies is associated with improved long-term outcomes, yet data on the early use of prostacyclin pathway agents are limited. ...Time from diagnosis was prognostic of morbidity/mortality, with newly di …
BACKGROUND: Early initiation of pulmonary arterial hypertension (PAH) therapies is associated with improved long-term outcomes, yet d …
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galiè N, Hoeper MM. Sitbon O, et al. Among authors: rubin lj. J Heart Lung Transplant. 2020 Apr;39(4):300-309. doi: 10.1016/j.healun.2019.12.013. Epub 2020 Jan 21. J Heart Lung Transplant. 2020. PMID: 32061506 Free article. Clinical Trial.
BACKGROUND: Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the noninvasive French risk assessment approach (number of low-risk criteria based on the European Society of Cardiology and European Respiratory Society guidelines) and Registry to Evaluat …
BACKGROUND: Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the noninvasive French risk assessment approach ( …
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.
Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R. Torbicki A, et al. Among authors: rubin lj. Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31109190 Free PMC article.
Methods and Results SERAPHIN enrolled and followed patients in the same time frame as the US Registry to Evaluate Early And Long-term PAH Disease Management, providing an opportunity to compare observed survival for SERAPHIN patients with predicted survival had they receiv …
Methods and Results SERAPHIN enrolled and followed patients in the same time frame as the US Registry to Evaluate Early And Long-term …
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. Chin KM, et al. Among authors: rubin lj. Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360. Circulation. 2019. PMID: 30982349 Free PMC article. Clinical Trial.
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group. Vachiéry JL, et al. Among authors: rubin lj. J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22. J Heart Lung Transplant. 2019. PMID: 30522722 Free article. Clinical Trial.
BACKGROUND: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arter …
BACKGROUND: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was ass …
Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.
Frost AE, Hoeper MM, Barberá JA, Vachiery JL, Blair C, Langley J, Rubin LJ. Frost AE, et al. Among authors: rubin lj. J Heart Lung Transplant. 2018 Dec;37(12):1410-1417. doi: 10.1016/j.healun.2018.07.001. Epub 2018 Sep 9. J Heart Lung Transplant. 2018. PMID: 30209017 Clinical Trial.
BACKGROUND: The multinational AMBITION study demonstrated a 50% risk reduction in time to first clinical failure event (TtCF, a composite of death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinica …
BACKGROUND: The multinational AMBITION study demonstrated a 50% risk reduction in time to first clinical failure event (TtCF, a composite of …
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.
Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G. Souza R, et al. Among authors: rubin lj. PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018. PLoS One. 2018. PMID: 29590122 Free PMC article. Clinical Trial.
Using the randomized controlled trial of macitentan in pulmonary arterial hypertension (SERAPHIN), the association between six-minute walk distance and long-term outcomes was explored. METHODS: Patients with six-minute walk distance data at Month 6 were dichotomized as abo …
Using the randomized controlled trial of macitentan in pulmonary arterial hypertension (SERAPHIN), the association between six-minute walk d …
Cor Pulmonale Revisited. From Ferrer and Harvey to the Present.
Rubin LJ. Rubin LJ. Ann Am Thorac Soc. 2018 Feb;15(Suppl 1):S42-S44. doi: 10.1513/AnnalsATS.201710-772KV. Ann Am Thorac Soc. 2018. PMID: 29461887 Review.
The term cor pulmonale has traditionally been used as a synonym for right heart failure due to chronic respiratory diseases, although this condition is less frequently seen in the modern era because of the use of long-term oxygen therapy along with aggressive measur …
The term cor pulmonale has traditionally been used as a synonym for right heart failure due to chronic respiratory diseases, although …
52 results